EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies

Paloma García Quilón, Greta Volpedo, Serena Cappato, Loretta Ferrera, Federico Zara, Renata Bocciardi, Antonella Riva iD, Pasquale Striano

CNS Neuroscience & Therapeutics · 2024-11 · 30 (11)

DOI: 10.1111/cns.70050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 11.11.2024. Verfasst von Paloma García Quilón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Epilepsy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developmental and epileptic encephalopathies (DEEs) comprise a complex spectrum of neurological disorders characterized by neurodevelopmental delay and early‐onset seizures primarily caused by diverse genetic mutations. Traditional treatments have largely been symptomatic, focusing on seizure control without addressing the underlying genetic causes. The advent of gene therapy, particularly through antisense oligonucleotides (ASOs), offers a promising avenue toward targeted therapeutic interventions. ASOs by virtue of their ability to modulate gene expression at the mRNA level represent a sophisticated approach to counteract the effects of pathogenic mutations. This review delves into the recent advancements in ASO technology, highlighting its application in preclinical and clinical settings for DEEs. We present evidence of the efficacy of ASOs in ameliorating disease phenotypes in vitro and in vivo, alongside promising outcomes from ongoing clinical trials. The therapeutic landscape for DEEs is on the cusp of significant transformation, underscored by the potential of ASOs to offer precise, personalized, treatments that extend beyond symptomatic relief to potentially rectify the genetic underpinnings of these disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseEpilepsyHumansAnimalsPrecision MedicineGenetic TherapyBrain Diseases

Stichwörter der Autor:innen

DEEantisense oligonucleotidesclinical studiesepilepsygene therapypreclinical studies

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

ORCID-Profile: Antonella Riva

Zitieren

APA

Quilón, P. G., Volpedo, G., Cappato, S., Ferrera, L., Zara, F., Bocciardi, R., Riva, A., & Striano, P. (2024). Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. CNS Neuroscience & Therapeutics, 30(11). https://doi.org/10.1111/cns.70050

Vancouver

Quilón PG, Volpedo G, Cappato S, Ferrera L, Zara F, Bocciardi R, et al. Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. CNS Neuroscience & Therapeutics. 2024;30(11). doi:10.1111/cns.70050

BibTeX
@article{Quiln2024,
  author = {Quilón, Paloma García and Volpedo, Greta and Cappato, Serena and Ferrera, Loretta and Zara, Federico and Bocciardi, Renata and Riva, Antonella and Striano, Pasquale},
  title = {Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  volume = {30},
  number = {11},
  doi = {10.1111/cns.70050}
}
Kostenlos starten →